Antitubercular agent-31

Antitubercular agent-31 (Compound 2) is an antitubercular agent with an MIC of 0.03 μM against M. tuberculosis H37Rv. Antitubercular agent-31 also inhibits DprE1 with an IC50 of 1.1 μM[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Bacterial

IC50: 1.1 μM (DprE1)[1]

Antitubercular agent-31 (Compound 2) shows aqueous solubility of 0.81 μg/mL in phosphate buffer pH 7.4. The plasma protein binding property is 97.9%[1]. Antitubercular agent-31 shows acceptable liver microsomal stability in human and mouse liver microsomes[1].

Antitubercular agent-31 (10 or 2 mg/kg; p.o. or i.v.; once) displays an acceptable pharmacokinetics (PK) profile with only dosing i.v., shows either poor membrane permeability or rapid clearance rate in vivo[1]. Animal Model: Male Balb/c mice[1] Dosage: 10 mg/kg or 2 mg/kg Administration: Oral (10 mg/kg) or intravenous (2 mg/kg) administration (Pharmacokinetic Analysis) Result: PK data for Antitubercular agent-31 (Compound 2),iv, 2mg/kg[1]. Tmax (h) Cmax (ng/mL) AUC0-t (h*ng/mL) AUC0-∞ (h*ng/mL) T1/2 (h) CL/F (mL/h/kg) MRT0-∞ (h) 0.1±0.0 463.4±103.4 158.2±18.8 161.3±18.6 0.3±0.0 12515.5±1379.7 0.4±0.0 No compound signal was detected at oral administration.

[1]. Shi R, et al. Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents. ACS Med Chem Lett. 2022 Mar 10;13(4):593-598.